JP2022551282A5 - - Google Patents

Info

Publication number
JP2022551282A5
JP2022551282A5 JP2022520724A JP2022520724A JP2022551282A5 JP 2022551282 A5 JP2022551282 A5 JP 2022551282A5 JP 2022520724 A JP2022520724 A JP 2022520724A JP 2022520724 A JP2022520724 A JP 2022520724A JP 2022551282 A5 JP2022551282 A5 JP 2022551282A5
Authority
JP
Japan
Prior art keywords
cysteine
approximately
composition according
absent
valine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022520724A
Other languages
English (en)
Japanese (ja)
Other versions
JP7761557B2 (ja
JP2022551282A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2020/013467 external-priority patent/WO2021066600A1/ko
Publication of JP2022551282A publication Critical patent/JP2022551282A/ja
Publication of JP2022551282A5 publication Critical patent/JP2022551282A5/ja
Priority to JP2025107100A priority Critical patent/JP2025144567A/ja
Application granted granted Critical
Publication of JP7761557B2 publication Critical patent/JP7761557B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022520724A 2019-10-04 2020-10-05 グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用 Active JP7761557B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025107100A JP2025144567A (ja) 2019-10-04 2025-06-25 グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2019-0123250 2019-10-04
KR20190123250 2019-10-04
PCT/KR2020/013467 WO2021066600A1 (ko) 2019-10-04 2020-10-05 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025107100A Division JP2025144567A (ja) 2019-10-04 2025-06-25 グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用

Publications (3)

Publication Number Publication Date
JP2022551282A JP2022551282A (ja) 2022-12-08
JP2022551282A5 true JP2022551282A5 (https=) 2023-10-16
JP7761557B2 JP7761557B2 (ja) 2025-10-28

Family

ID=75338451

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022520724A Active JP7761557B2 (ja) 2019-10-04 2020-10-05 グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用
JP2025107100A Abandoned JP2025144567A (ja) 2019-10-04 2025-06-25 グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025107100A Abandoned JP2025144567A (ja) 2019-10-04 2025-06-25 グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用

Country Status (6)

Country Link
US (1) US20230000950A1 (https=)
EP (1) EP4043026A4 (https=)
JP (2) JP7761557B2 (https=)
KR (1) KR20210040818A (https=)
CN (1) CN114786706A (https=)
WO (1) WO2021066600A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4230640A4 (en) * 2020-10-16 2024-11-20 Hanmi Pharm. Co., Ltd. GLP-1/GIP DOUBLE AGONIST, LONG-ACTING CONJUGATE THEREOF AND PHARMACEUTICAL COMPOSITION THEREOF
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CN117157094A (zh) * 2021-04-09 2023-12-01 韩美药品株式会社 包括胰高血糖素衍生物的用于预防或治疗慢性肾病的药物组合物
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
KR20230095666A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도
CN116120403B (zh) * 2022-11-01 2026-03-17 成都普康唯新生物科技有限公司 一种固相制备Tirzepatide的方法
WO2024098718A1 (zh) * 2022-11-07 2024-05-16 内蒙古博睿精创科技有限公司 一种新型长效多肽化合物、组合物及其应用
CN116942612A (zh) * 2023-08-30 2023-10-27 重庆派金生物科技有限公司 一种脂肪酸修饰的胰高血糖素样肽类似物的鼻用喷雾剂及其应用
WO2025101959A1 (en) * 2023-11-08 2025-05-15 Renbio, Inc. Plasmid dna constructs for peptide hormone expression
KR20250177375A (ko) * 2024-06-13 2025-12-23 한미약품 주식회사 Glp-1, gip, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 지질 대사 질환 예방 또는 치료용 약학적 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US8703701B2 (en) * 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
IN2014MN02304A (https=) 2012-05-03 2015-08-07 Zealand Pharma As
SI3004155T1 (sl) 2013-05-28 2022-02-28 Takeda Pharmaceutical Company Limited Peptidna spojina
WO2015067715A2 (en) * 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2015086728A1 (en) * 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080154B1 (en) * 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TWI582109B (zh) * 2015-01-09 2017-05-11 美國禮來大藥廠 Ｇｉｐ及ｇｌｐ－１共促效劑化合物
WO2016198624A1 (en) * 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
EP4523705A3 (en) * 2015-06-30 2025-06-11 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
SG11201805586SA (en) * 2015-12-31 2018-07-30 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
EP3479841A4 (en) * 2016-06-29 2020-03-04 Hanmi Pharm. Co., Ltd. GLUCAGON DERIVATIVE, CONJUGATE THEREOF, COMPOSITION THEREOF AND THERAPEUTIC USE THEREOF
TW201833131A (zh) * 2016-12-02 2018-09-16 法商賽諾菲公司 作為胜肽類ｇｌｐ１／升糖素／ｇｉｐ受體促效劑之新化合物
AR110300A1 (es) * 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip
WO2020071865A1 (ko) * 2018-10-04 2020-04-09 한미약품 주식회사 글루카곤 및 이를 포함하는 조합물의 치료학적 용도

Similar Documents

Publication Publication Date Title
JP2022551282A5 (https=)
JP6936366B2 (ja) 胆汁酸に関係した障害の治療方法
RU2671088C2 (ru) Агонисты рецепторов глюкагона/glp-1 для лечения ожирения
TWI670281B (zh) Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法
JP6898231B6 (ja) Ｇｉｐアゴニスト化合物及び方法
JP7761557B2 (ja) グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用
TWI708614B (zh) 包含調酸素衍生物之治療高血脂症的組成物
ES3023833T3 (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
JP2021518745A5 (ja) アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物
JP2021167352A (ja) 免疫グロブリンＦｃフラグメント結合を用いたタンパク質及びペプチドの溶解度を改善する方法
JP2018526333A5 (https=)
JP2014530868A5 (https=)
JP2013534919A (ja) グルカゴン類似体
JP2014504597A (ja) アシル化グルカゴン類似体とインスリン類似体の組合せ物
EP2844269A1 (en) Transmucosal delivery of engineered polypeptides
CN107849110A (zh) 选择性pyy化合物及其用途
CN105829339A (zh) 胰高血糖素-glp-1-gip三重激动剂化合物
EA031928B1 (ru) Композиция для лечения диабета или диажирения, содержащая конъюгат аналога оксинтомодулина
JP2015504073A5 (https=)
JP2018504901A5 (https=)
JP2025178483A (ja) ポリペプチドを含む医薬組成物
JP2018505153A (ja) グルカゴン誘導体
JP2023538236A5 (https=)
JP2013511287A (ja) ポリペプチド・コンジュゲート
IL299778A (en) Therapeutic use of glucagon derivative or conjugate thereof for liver disease